Chemo plus surgery for recurrent lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 trial tests whether giving chemotherapy along with surgery is safe and tolerable for people with recurrent non-small cell lung cancer. It may help guide future treatment for cancer that has returned, especially if it has not spread to distant sites.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 75 years old or younger
- Have non-small cell lung cancer confirmed by a biopsy (histologically proven)
- Be in good enough health to do daily activities (WHO performance status 0 or 1)
- Have no severe problems with major organs (like heart, liver, or kidneys)
- Have not had any prior chemotherapy for cancer
- Have lung cancer that is not Stage IV or known to have spread to distant parts (metastasis) on pre-surgery scans including a pleural CT scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This trial studies whether adding chemotherapy after surgery helps people with early-stage lung adenocarcinoma that has a micropapillary pattern. It’s testing whether chemotherapy given after complete tumor removal can improve outcomes compared with surgery alone.
This trial tests giving chemotherapy combined with the immunotherapy drug sintilimab before surgery for people with stage IIA to IIIB non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial studies whether adding an immune medicine (durvalumab) to standard chemoradiation, followed by surgery, improves outcomes for people with certain operable non-small cell lung cancers. It also checks safety and side effects.
This trial tests whether giving an immune-boosting drug (Tα1) along with chemotherapy and immunotherapy before surgery helps people with stage II-IIIB non-small cell lung cancer that can be removed. It aims to see if this combination makes the cancer shrink more and improves outcomes.
Hear when a new Recurrent Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.